Sight Sciences, Inc. Stock Price, News & Analysis

Sight Sciences (SGHT) reported Q4 2024 revenue of $19.1M, up 2% YoY, while full-year 2024 revenue decreased 1% to $79.9M. The company's Surgical Glaucoma segment revenue grew 9% to $18.8M in Q4, while Dry Eye revenue declined to $0.3M from $1.6M YoY.

Q4 gross margin improved to 87% from 85% YoY. Full-year operating expenses decreased 6% to $118.8M, with net loss improving to $51.5M ($1.03 per share) from $55.5M ($1.14 per share) in 2023. Cash position stood at $120.4M as of December 31, 2024.

For 2025, SGHT projects revenue between $70-75M, representing a 6-12% decline, primarily due to Medicare LCD restrictions on multiple MIGS procedures during cataract surgery. The company expects adjusted operating expenses of $105-107M for 2025, a 4-6% increase from 2024.

Sight Sciences (SGHT) announced multiple presentations featuring the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting. A meta-analysis of 22 studies with 2,379 eyes demonstrated the system's effectiveness in reducing intraocular pressure and medication dependency for up to 36 months.

Key findings from the IRIS® Registry, one of the largest specialty clinical data registries, showed significant clinical outcomes across diverse patient populations. The data revealed that MIGS procedures using OMNI, when combined with cataract surgery in Black patients, resulted in significant IOP reductions through 24 months and medication reductions through 36 months.

The studies demonstrated favorable efficacy and safety profiles across different glaucoma severity levels, including standalone treatments in both phakic and pseudophakic eyes.

Sight Sciences (SGHT) has announced it will release its fourth quarter and full year 2024 financial results after market close on March 5, 2025. The eyecare technology company will host a conference call to discuss the results at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access the live webcast and replay of the event through the company's website at www.sightsciences.com in the Investors page under News & Events section. The webcast replay will be available for at least 90 days following the event.

Sight Sciences (Nasdaq: SGHT), an eyecare technology company, has announced its participation in Citi's 2025 Unplugged MedTech and Life Sciences Access Day in New York. The company, which specializes in developing innovative interventional technologies for eye care, will deliver a presentation on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET.

Investors and interested parties can access both the live presentation and archived webcast through the company's investor relations website at investors.sightsciences.com. This presentation represents an opportunity for stakeholders to gain insights into the company's developments and strategies in transformative eye care solutions.

Sight Sciences (SGHT) has released preliminary Q4 and FY2024 financial highlights. Q4 2024 total revenue is expected between $18.9-19.1M, up 1% year-over-year, with Surgical Glaucoma revenue increasing 9% to $18.7-18.8M, while Dry Eye revenue declined to $0.2-0.3M from $1.6M.

Full year 2024 revenue is projected at $79.7-79.9M, down 2% from 2023. The company ended 2024 with approximately $120M in cash, generating $1.4M in Q4 (including a $5M term loan drawdown) compared to using $6.4M in Q4 2023. Annual cash usage decreased to $18.1M from $46.9M in 2023.

Performance was impacted by new Medicare LCD restrictions on multiple MIGS procedures during cataract surgery. The company aims to achieve cash flow breakeven without additional equity capital.

Sight Sciences (NASDAQ: SGHT) has published a landmark 36-month study demonstrating the long-term effectiveness of its OMNI® Surgical System in managing primary open-angle glaucoma (POAG). The study, published in the American Journal of Ophthalmology, analyzed real-world data from 230 eyes of 196 patients through the American Academy of Ophthalmology IRIS® Registry.

Key findings show significant and sustained reductions in intraocular pressure (IOP) over 36 months, with mean reductions ranging from 5.6 to 7.1 mmHg. Patients with baseline IOP greater than 18 mmHg showed even greater reductions of up to 8.9 mmHg. The study also reported decreased medication dependence, with mean medication use dropping from 2.1 at baseline to 1.1-1.6 between months 6 and 36.

This represents the largest study to date evaluating clinical outcomes of standalone canaloplasty and trabeculotomy, supporting OMNI's effectiveness as a minimally invasive glaucoma surgery (MIGS) option.

Sight Sciences (SGHT) announced results of a Budget Impact Analysis (BIA) for its TearCare® System in treating Meibomian Gland Disease (MGD)-associated dry eye disease. The study, published in Expert Review of Ophthalmology, compared TearCare to prescription medications like Restasis and Xiidra over a two-year period.

The analysis revealed that a 20% increase in TearCare's market share versus prescription medications would generate estimated savings of $36.87 per member per year in a health plan covering one million lives. The study demonstrated that higher TearCare utilization correlates with increased cost savings from a US payer perspective.

Sight Sciences (Nasdaq: SGHT), an eyecare technology company, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. The company's management will deliver a presentation on Tuesday, December 3, 2024, at 12:30 pm PT / 3:30 pm ET. A live webcast and recording of the fireside chat will be available to interested parties through the 'Investors' section of Sight Sciences' website at investors.sightsciences.com.

Sight Sciences reported its Q3 2024 financial results and updated its full-year 2024 adjusted operating expense guidance. The company generated total revenue of $20.2 million, a 1% increase year-over-year, and achieved a positive cash flow of $0.4 million compared to a $10.0 million cash usage in Q3 2023. Gross profit was $16.9 million with a gross margin of 84%. The net loss was reduced to $11.1 million ($0.22 per share) from $13.0 million ($0.27 per share) in Q3 2023. Operating expenses decreased by 8% to $28.1 million. The company also announced the Final LCDs that confirm Medicare coverage for certain glaucoma procedures, effective November 17, 2024. Sight Sciences maintains its revenue guidance of $81.0-$83.0 million for 2024 but revises its adjusted operating expenses guidance to $104.0-$106.0 million.